drugset / Trial / NCT05044819
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Phase 4
Active not recruiting
154 enrolled
Jazz Pharmaceuticals
Jazz Pharmaceuticals Research UK Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
Timeline
- Start
- 2021-07-07
- Primary completion
- 2027-08-01
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 10 mg/kg | Oral |